Bristol-Myers Squibb Co [BMY] stock is trading at $55.45, up 2.08%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BMY shares have gain 5.34% over the last week, with a monthly amount glided 2.76%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bristol-Myers Squibb Co [NYSE: BMY] stock has seen the most recent analyst activity on October 25, 2024, when Citigroup downgraded its rating to a Neutral and also revised its price target to $55 from $75. Previously, Bernstein started tracking the stock with Mkt Perform rating on October 17, 2024, and set its price target to $56. On July 29, 2024, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $41 on the stock. Societe Generale downgraded its rating to a Hold. Redburn Atlantic downgraded its rating to a Neutral and reduced its price target to $54 on February 06, 2024. BofA Securities downgraded its rating to Neutral for this stock on January 03, 2024, and downed its price target to $60. In a note dated November 15, 2023, Cantor Fitzgerald downgraded an Neutral rating on this stock and revised its target price from $68 to $55.
Bristol-Myers Squibb Co [BMY] stock has fluctuated between $39.35 and $56.20 over the past year. Currently, Wall Street analysts expect the stock to reach $64.57 within the next 12 months. Bristol-Myers Squibb Co [NYSE: BMY] shares were valued at $55.45 at the most recent close of the market. An investor can expect a potential return of 16.45% based on the average BMY price forecast.
Analyzing the BMY fundamentals
Bristol-Myers Squibb Co [NYSE:BMY] reported sales of 47.44B for the trailing twelve months, which represents a growth of 8.44%. Gross Profit Margin for this corporation currently stands at 0.7% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.36 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.59 points at the first support level, and at 53.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.04, and for the 2nd resistance point, it is at 56.63.
Ratios To Look Out For
For context, Bristol-Myers Squibb Co’s Current Ratio is 1.24. Also, the Quick Ratio is 1.09, while the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 2.31, the price to book ratio is 6.56.
Transactions by insiders
Recent insider trading involved Holzer Phil M, Officer, that happened on Nov 04 ’24 when 700.0 shares were purchased. Chief Executive Officer, BOERNER CHRISTOPHER S. completed a deal on Dec 05 ’23 to buy 2000.0 shares. Meanwhile, Chief Executive Officer BOERNER CHRISTOPHER S. bought 3071.0 shares on Nov 28 ’23.
